Company intelligence / Profile preview

LEAC-102

Ownership: Private
Development stage: Other

Overview

Leaderna Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation siRNA therapies. The company utilizes its proprietary L-GalNAc liver-targeting delivery platform to create highly potent and durable RNA interference treatments for metabolic and cardiovascular diseases. Its lead candidate, LEAC-102, is an siRNA targeting ANGPTL3 designed to treat patients with severe hypertriglyceridemia and other forms of dyslipidemia. Leaderna aims to provide long-acting, subcutaneous therapeutic options that significantly reduce lipid levels and cardiovascular risk.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Beyond the preview

Go deeper on LEAC-102.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAC-102.

Explore the full profile